WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, today announced that, as a result of its strategic collaborations, seven abstracts have been accepted to the American Society of Clinical Oncology (ASCO) Annual Meeting. All abstracts to be published in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.
“We are honored to have multiple abstracts accepted by ASCO 2020. The studies demonstrate the clinical utility of BostonGene‘s advanced precision medicine capabilities and our commitment to transform the lives of cancer patients,” said Andrew Feinberg, President & CEO at BostonGene.
Details of abstract presentations are as follows:
| 1. | Abstract Number: 8055* |
Title: “Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance” |
|
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
|
Presenter: Krystle Nomie, PhD, BostonGene |
|
Poster: 388 |
|
Tumor-immune molecular programs were characterized from over 200 mantle cell lymphoma samples and correlated with response to ibrutinib. |
|
|
|
Research conducted with The University of Texas MD Anderson Cancer Center |
|
|
|
| 2. | Abstract Number: 6561* |
Title: “Immune functional portraits of head and neck cancer using next generation sequencing” |
|
Session: Head and Neck Cancer |
|
Presenter: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital |
|
Poster: 222 |
|
BostonGene’s comprehensive, integrated analysis of WES and RNAseq was used to characterize the cellular composition and functional state of over 1,400 head and neck tumors and their tumor microenvironment. |
|
|
|
Research conducted with Massachusetts General Hospital |
|
| 3. | Abstract Number: 8054* |
Title: “Identification of Predicted Neoantigen Vaccine Candidates in Follicular Lymphoma Patients” |
|
Session Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
|
Presenter: Cody Ramirez at Washington University in St Louis |
|
Poster: 387 |
|
|
|
Tumor-specific mutant antigens (TSMAs) that can be targeted by vaccination were studied in follicular lymphoma patients and led to a first-in-human pilot trial of a personalized TSMA vaccine combined with immunotherapy. |
|
|
|
Research conducted with Washington University in St Louis |
|
|
|
| 4. | Abstract Number: e20065 |
Title: “Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma” |
|
First Author: Krystle Nomie, PhD, BostonGene |
|
|
|
Research conducted with The University of Texas MD Anderson Cancer Center |
|
| 5. | Abstract Number: e21026 |
Title: “Non-small cell lung cancer: Analysis using mass cytometry and next generation sequencing reveals new opportunities for the development of personalized therapies” |
|
First Author: Susan Raju Paul, MBBS, Vaccine and Immunotherapy Center, Massachusetts General Hospital |
|
|
|
Research conducted with Massachusetts General Hospital |
|
| 6. | Abstract Number: e17106 |
Title: “Integrated single-cell spatial multi-omics of intratumor heterogeneity in renal cell carcinoma” |
|
First Author: James Hsieh, MD, PhD at Washington University in St. Louis |
|
|
|
Research conducted with Washington University in St Louis |
|
|
|
| 7. | Abstract Number: e17506 |
Title: “Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome” |
|
First Author: Eric H. Kim, MD at Washington University in St. Louis |
|
|
|
Research conducted with Washington University in St Louis |
*Abstracts to be presented as posters at the 2020 ASCO Annual Virtual Meeting from May 29-31, 2020
About BostonGene Corporation
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.
